Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
| Autor: | Shitara, Kohei, Moehler, Markus H., Ajani, Jaffer A., Shen, Lin, Garrido, Marcelo, Gallardo, Carlos, Wyrwicz, Lucjan S., Yamaguchi, Kensei, Cleary, James M., Elimova, Elena, Bruges Maya, Ricardo Elias, Karamouzis, Michalis, Skoczylas, Tomasz, Bragagnoli, Arinilda, Liu, Tianshu, Tehfe, Mustapha, Feeney, Kynan, Wang, Rui, Nathani, Raheel, Janjigian, Yelena Y. |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p306-306, 185p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|